Condition: High-grade Squamous Intraepithelial Lesion (HSIL) · Sponsor: Newish Biotech (Wuxi) Co., Ltd.
This is a randomized, double-blind, placebo controlled Phase 2 study to determine the efficacy and safety of NWRD08 administered by intramuscular (IM) injection followed by electroporation (EP) in adult women with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL) (cervical intraepithelial neoplasia grade 2 \[CIN2\] or grade 3 \[CIN3\]) associated with human papillomavirus (HPV) 16 and/or HPV18.
This description comes directly from the study's public registry record.
Yang Xiang, M.D. · +86-010-69155635 · xiangy@pumch.cn
Fang Jiang · +86-010-69155635 · 13671170943@163.com
Always discuss trial participation with your own doctor first.
| Cancer Institute and Hospital Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Obstetrics and Gynecology Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Peking University First Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Peking Union Medical College Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The Second Hospital of Shanxi Medical University | Taiyuan, Shanxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07175662